Direct Therapeutics, Inc.

Direct Therapeutics, Inc. is a development-stage pharmaceutical company using its patented Solvent-Facilitated Perfusion technology to create new drugs for the localized and regional treatment of solid-tumor cancers. Our products are designed for direct injection to target tissue with minimal invasion of healthy tissue. They contain active ingredients in organic solvent vehicles that facilitate the penetration of the drug throughout tumor tissue and into tumor cells. In contrast to "sustained release" or "controlled release" products, our products rapidly, selectively, and thoroughly saturate tumors with doses of potent chemotherapeutic agents unachievable by other means. We have demonstrated that these products, when directly applied by needle or catheter to solid tumors, perfuse preferentially throughout the tumor, leading to rapid, selective death of cancerous tissue.
We have completed two Phase I/II studies of our lead product, DTI-015 in the United States for the treatment of brain cancer, and will start our first European trial of DTI-015 in Q1 2003. In November 2002 , we received notice from the US FDA that the company had satisfied the necessary requirements to initiate a Phase III product-registration trial of DTI-015 in patients with glioblastoma multiforme, the most common and deadly form of brain cancer. In addition, we are pursuing development of new Solvent-Facilitated Perfusion products, which have shown positive results in pre-clinical studies.

Contact Details: 460 Seaport Court, Suite 220 Redwood California 94063 United States of America Tel: Fax: Email: main@directtherapeutics.com WWW: www.directtherapeutics.com/

Loading...

BioNews Results for Direct Therapeutics, Inc.:
Research and Markets: Hepatitis C Virus and Therapeutics Report - A Global Update of Market...	Forbes.com:  Nov 19 2009 5:41PM Matching: direct therapeutics inc
Sunesis Reports Data From Nonclinical Studies of Voreloxin at AACR-EORTC-NCI Conference	Genetic Engineering News:  Nov 18 2009 6:40PM Matching: direct therapeutics inc
Sunesis Reports Data From Nonclinical Studies of Voreloxin at AACR-EORTC-NCI Conference	Freshnews.com:  Nov 18 2009 5:54PM Matching: direct therapeutics inc
Novelos Therapeutics and Academic Collaborators Present Scientific Findings at International Cancer Conference	Genetic Engineering News:  Nov 16 2009 2:57PM Matching: direct therapeutics inc
Novelos Therapeutics and Academic Collaborators Present Scientific Findings at International Cancer Conference	Yahoo! Canada:  Nov 16 2009 3:40PM Matching: direct therapeutics inc
Promote your company here: BioNewsCast - Press Release Distribution	→View more Direct Therapeutics, Inc. news.

Direct Therapeutics, Inc. Patents:
US Patent No.	Title
6753005	Method for tissue perfusion
6203526	Apparatus for preventing loss of a composition during a medical procedure

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 406 times since April 2007, the link to the organisation's website has been followed 81 times

Recent Search Terms used to find this page: direct therapeutics inc | Direct Therapeutics | U S patent Direct Therapeutics | Direct therapeutics inc | Direct therapeutics inc | .

Search for more companies in Redwood

Search for more companies in California

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Direct Therapeutics, Inc.